News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Sanofi-Aventis (France) Pulls Obesity Drug Application in U.S.
June 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - Sanofi-Aventis said on Friday it was withdrawing its application to sell obesity drug rimonabant -- its biggest new drug hope -- in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Sanofi
MORE ON THIS TOPIC
FDA
7 FDA decisions to watch for in Q3
July 2, 2026
·
7 min read
·
Tristan Manalac
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
·
2 min read
·
Tristan Manalac
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
